Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 10, 2013, Pages 2081-2094

  Kulkarni, Viraj ^a   Rosati, Margherita ^a   Bear, Jenifer ^a   Pilkington, Guy R ^a   Jalah, Rashmi ^a   Bergamaschi, Cristina ^a   Singh, Ashish K ^a   Alicea, Candido ^a   Chowdhury, Bhabadeb ^a   Zhang, Gen Mu ^a   Kim, Eun Young ^b   Wolinsky, Steven M ^b   Huang, Wensheng ^c   Guan, Yongjun ^c   La Branche, Celia ^d   Montefiori, David C ^d   Broderick, Kate E ^e   Sardesai, Niranjan Y ^e   Valentin, Antonio ^a   Felber, Barbara K ^a   Pavlakis, George N ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Inovio Pharmaceuticals Inc   (United States)

Author keywords

Avidity; Binding antibody; DNA vaccine; Effector memory; HIV; In vivo electroporation; Intradermal; Intramuscular; Neutralizing antibody; SIVmac239; SIVmac251; SIVsmE660; Transitional memory; Transmitted Env

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; GRANZYME B; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; DRUG ADMINISTRATION ROUTE; ELECTROPORATION; EMBRYO; FEMALE; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MACACA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS ENVELOPE; VIRUS STRAIN;

AVIDITY; BINDING ANTIBODY; DNA VACCINE; EFFECTOR MEMORY; HIV; IN VIVO ELECTROPORATION; INTRADERMAL; INTRAMUSCULAR; NEUTRALIZING ANTIBODY; SIVMAC239; SIVMAC251; SIVSME660; TRANSITIONAL MEMORY; TRANSMITTED ENV;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; ELECTROPORATION; FEMALE; GENE PRODUCTS, ENV; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; MICE; MICE, INBRED BALB C; SAIDS VACCINES; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VACCINATION; VACCINES, DNA;

EID: 84885091548     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25473     Document Type: Article

References (65)

1. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol 2011;23:421-9; PMID:21530212; http://dx.doi.org/10.1016/j.coi.2011.03.008
2. Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB. Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol 2011;1:233-40; PMID:22440782; http://dx.doi.org/10.1016/j.coviro.2011.08. 003
3. Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immu no therapeutics: current clinical developments. MolTher 2009;17:585-92; PMID:19223870; http://dx.doi.org/10.1038/ mt.2009.5
4. Lori E DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS. Expert Rev Vaccines 2011;10:1371-84; PMID:21988301; http://dx.doi.org/10.1586/erv.11.118
5. Sullivan SM, Doukas J, Hartikka J, Smith L, Rolland A. Vaxfectin: a versatile adjuvant for plasmid DNA-and protein-based vaccines. Expert Opin Drug Deliv 2010;7:1433-46; PMID:21118032; http://dx.doi.org/10.1517/17425247.2010. 538047
6. Hallengard D, Brave A, Isaguliants M, Blomberg P, Enger J, Stout R, et al. A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet Vaccines Ther 2012;10:5; PMID:22873174; http://dx.doi.org/10.1186/1479-0556-10-5
7. Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009;4:e7226; PMID:19789652; http://dx.doi.org/10.1371/journal.pone.0007226
8. Fuller DH, Simpson L, Cole KS, Clements JE, Panicali DL, Montelaro RC, et al. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol 1997;75:389-96; PMID:9315483; http://dx.doi.org/10.1038/icb.1997.61
9. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998;16:867-70; PMID:9743122; http://dx.doi.org/10.1038/ nbt0998-867
10. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999;6:508-14; PMID: 10476210; http://dx.doi.org/10. 1038/sj.gt.3300847
11. Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R. Electroporation- enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006;6:243-73; PMID: 16611045; http://dx.doi.org/10.2174/15665230677635 95 04
12. Rizzuto G, Cappelletti M, Maione D, Savino R, Lazzaro D, Costa P, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A 1999;96:6417-22; PMID: 10339602; http://dx.doi.org/10.1073/pnas.96.11.6417
13. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000;164:4635-40; PMID:10779767
14. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, Zur Megede J, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004;22:2489-93; PMID:15193413; http://dx.doi.org/10.1016/j.vaccine. 2003.11.073
15. Rosati M, Valentin A, Jalah R, Patel V, Von Gegerfelt A, Bergamaschi C, et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 2008;26:5223-9; PMID: 18468743; http:ZZdx.doi.org/10.1016/j.vaccine.2008.03.090
16. Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J, et al. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006;24:4503-9; PMID:16181711; http:ZZdx.doi.org/10. 1016/j.vaccine.2005.08.017
17. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007;81:5257-69; PMID: 17329330; http://dx.doi.org/10.1128/JVI.00055-07
18. Hirao LA, Wu L, Khan AS, Hokey DA, Yan J, Dai A, et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine 2008;26:#3112-20; PMID: 18430495; http://dx.doi.org/1 0.1016/j.vaccine.2008.02.036
19. Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota SA, Sidhu MK, et al. SIV DNA vaccine coadministered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 2005;34:262-70; PMID:16128921; http://dx.doi. Org/10.1111/j.1600-0684.2005. 00124.x
20. Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006;24:4677-87; PMID: 16288822; http://dx.doi.org/10.1016/j.vaccine.2005.10.035
21. Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006;24:4677-87; PMID: 16288822; http://dx.doi.org/10.1016/j.vaccine.2005.10.035
22. Robinson TM, Sidhu MK, Pavlakis GN, Felber BK, Silvera P, Lewis MG, et al. Macaques co-immunized with SIVgagZpol-HIVenv and IL-12 plasmid have increased cellular responses. J Med Primatol 2007;36:276-84; PMID: 17669216; http://dx.doi.org/10.1 1111/j.1600-0684.2007.00245.x
23. Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008;180:7969-79; PMID: 18523260
24. Jalah R, Patel V, Kulkarni V, Rosati M, Alicea C, Ganneru B, et al. IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. Hum Vaccin Immunother 2012;8:1620-9; PMID:22894956; http://dx.doi.org/1 0.4161/hv. 21407
25. Wmstone N, Wilson AJ, Morrow G, Boggiano C, Chiuchiolo MJ, Lopez M, et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J Virol 2011;85:9578-87; PMID:21734035; http://dx.doi.org/10. H28Z JVI.05060-11
26. Rosati M, Bergamaschi C, Valentin A, Kulkarni V, Jalah R, Alicea C, et al. DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A 2009;106:15831-6; PMID: 19717425; http://dx.doi.org/10.1073/pnas. 0902628106
27. Patel V, Valentin A, Kulkarni V, Rosati M, Bergamaschi C, Jalah R, et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 2010;28:4827-36; PMID:20451642; http://dx.doi.org/10.1016/j.vaccine.2010.04.064
28. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, et al. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A 2013;110:2975-80; PMID:23359688; http://dx.doi.org/10.1073/pnas. 1215393110
29. Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2011;203:95-102; PMID:21148501; http://dx.doi.org/10.10 93ZinfdisZjiq017
30. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009;83:4624-30; PMID:19211745; http://dx.doi.org/1 0.1128/JVI. 02335-08
31. Vasan S, Hurley A, Schlesinger SJ, Hannaman D, Gardiner DF, Dugin DP, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6:e19252; PMID:21603651; http://dx.doi.org/10.13 71/journal.pone.0019252
32. Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, et al.; NIAID HIV Vaccine Trials Network. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 andZor IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012;7:e29231; PMID:22242162; http://dx.doi.org/1 0.1371/journal.pone.0029231
33. Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, et al. Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol 2013;87:4584-95; PMID:23408608; http://dx.doi.org/10. H28/JVI.03507-12
34. Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009;206:117-34; PMID: 19414559; http://dx.doi.org/10.1084/jem.20082831
35. O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, Wrin T, et al. Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol 2010;84:1200-9; PMID:20702624; http://dx.doi.org/10. H28/JVI.00790-10
36. Yuste E, Johnson W, Pavlakis GN, Desrosiers RC. Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus. J Virol 2005;79:12455-63; PMID:16160173; http://dx.doi.org/10.1128/JVI.79.19. 12455-12463.2005
37. Rosati M, Von Gegerfelt A, Roth P, Alicea C, Valentin A, Robert-Guroff M, et al. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol 2005;79:8480-92; PMID: 15956591; http://dx.doi.org/1 0.1128/JVI.79.13.8480-8492.2005
38. Kulkarni V, Jalah R, Ganneru B, Bergamaschi C, Alicea C, Von Gegerfelt A, et al. Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques. Vaccine 2011;29:6742-54; PMID:21195080; http://dx.doi.org/10.1016/j.vaccine.2010.12.056
39. Kulkarni V, Rosati M, Valentin A, Ganneru B, Singh AK, Yan J, et al. HIV-1 p24 (gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One 2013;8:e60245; PMID:23555935; http://dx.doi.org/10.1371/journal. pone.0060245
40. Kutzler MA, Robinson TM, Chattergoon MA, Choo DK, Choo AY, Choe PY, et al. Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol 2005;175:112-23; PMID:15972637
41. Santra S, Liao HX, Zhang R, Muldoon M, Watson S, Fischer W, et al. Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010;16:324-8; PMID:20173754; http://dx.doi.org/10.1038/nm.2108
42. Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, Pavlakis GN. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992;66:7176-82; PMID: 1433510
43. Schwartz S, Felber BK, Pavlakis GN. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 1992;66:50-9; PMID:1727477
44. Valentin A, Chikhlikar P, Patel V, Rosati M, Maciel M, Chang KH, et al. Comparison of DNA vaccines producing HIV-1 Gag and LAMPZGag chimera in rhesus macaques reveals antigen-specific T-cell responses with distinct phenotypes. Vaccine 2009;27:4840-9; PMID: 19539586; http:ZZdx.doi.org/10.1016/j.vaccine. 2009.05.093
45. Nasioulas G, Zolotukhin AS, Tabernero C, Solomin L, Cunningham CP, Pavlakis GN, et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 1994;68:2986-93; PMID:8151769
46. Von Gegerfelt AS, Rosati M, Alicea C, Valentin A, Roth P, Bear J, et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 2007;81:1972-9; PMID: 17135321; http://dx.doi.org/10.1128/JVI.01990-06
47. Cristillo AD, Weiss D, Hudacik L, Restrepo S, Galmin L, Suschak J, et al. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation. Biochem Biophys Res Commun 2008;366:29-35; PMID:18036339; http://dx.doi.org/10.1016/j.bbrc.2007.11.052
48. Hirao LA, Hokey DA, Morrow MP, Jure-Kunkel MN, Weiner DB. Immune modulation through 4-IBB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge. PLoS One 2011;6:e24250; PMID:21935390; http://dx.doi.org/10.1371/journal.pone. 0024250
49. Hutnick NA, Myles DJ, Hirao L, Scott VL, Ferraro B, Khan AS, et al. An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine 2012;30:3202-8; PMID:22406458; http://dx.doi.org/1 0.1016/j.vaccine.2012.02.069
50. Yin J, Dai A, Lecureux J, Arango T, Kutzler MA, Yan J, et al. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation. Vaccine 2011;29:6763-70; PMID:21195801; http://dx.doi.org/10.1016/j.vaccine.2010.12.055
51. Hutnick NA, Myles DJ, Ferraro B, Lucke C, Lin F, Yan J, et al. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum Gene Ther 2012;23:943-50; PMID:22650607; http://dx.doi.org/10.1089/hum.2012.055
52. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. IntradermalZsubcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008;26:440-8; PMID: 18082294; http://dx.doi.org/1 0.1016/j.vaccine.2007.10.041
53. Lin F, Shen X, McCoy JR, Mendoza JM, Yan J, Kemmerrer SV, et al. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 2011;29:6771-80; PMID:21199706; http://dx.doi.org/1 0.1016/j.vaccine.2010.12.057
54. Lin F, Shen X, Kichaev G, Mendoza JM, Yang M, Armendi P, et al. Optimization of electroporationenhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods 2012;23:157-68; PMID:22794496; http://dx.doi.org/1 0.1089/hgtb.2011.209
55. Reuter MA, Yuan S, Marx PA, Kutzler MA, Weiner DB, Bette MR. DNA-based HIV vaccines do not induce generalized activation in mucosal tissue T cells. Hum Vaccin Immunother 2012;8:1648-53; PMID: 23111167; http://dx.doi.org/10.4161/hv. 22247
56. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985;228:1201-4; PMID:3159089; http://dx.doi.org/10.112 6/science. 315 90 89
57. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005;43:406-13; PMID: 15635002; http://dx.doi.org/10.1128/JCM.43. 1.406-413.2005
58. Chertova E, Bergamaschi C, Chertov O, Sowder R, Bear J, Roser JD, et al. Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15-IL-15 Rot Cytokine Compared to IL-15 Monomer. J Biol Chem 2013;288:18093-103; PMID:23649624; http://dx.doi.org/10.1074/j b c. M113.461756
59. Connor RL, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995;206:935-44; PMID:7531918; http://dx.doi.org/10.1006/viro.1995.1016
60. Von Gegerfelt AS, Liska V, Li PL, McClure HM, Horie K, Nappi F, et al. Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. J Virol 2002;76:96-104; PMID: 11739675; http://dx.doi.org/10. 1128/JVI.76. L96-104.2002
61. Broderick KE, Shen X, Soderholm J, Lin F, McCoy J, Khan AS, et al. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther 2011;18:258-65; PMID:20962869; http://dx.doi.org/10.1038/gt.2010.137
62. Tjelle TE, Salte R, Mathiesen I, Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 2006;24:4667-70; PMID: 16162367; http://dx.doi.org/10.1016/j.vaccine.2005.08.068
63. Guan Y, Sajadi MM, Kamin-Lewis R, Fouts TR, Dimitrov A, Zhang Z, et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc Natl Acad Sci U S A 2009;106:3952-7; PMID: 19225108; http://dx.doi.org/10.1073/pnas.0813392106
64. Moore JP, Wallace LA, Follett EA, McKeating JA. An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. AIDS 1989;3:155-63; PMID:2540772; http://dx.doi.org/10.1097/ 00002030-198903000-00006
65. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2005; Chapter 12:Unit 12 1.